Research programme: substance P derivative - ImmuneRegen
Alternative Names: Homspera; Radilex; Sar9, Met (O2)11-Substance P; ViprovexLatest Information Update: 02 Oct 2021
At a glance
- Originator ImmuneRegen BioSciences
- Developer GenPhar; Hyperion Biotechnology; ImmuneRegen BioSciences
- Class Adjuvants; Antineoplastics; Antitoxins; Antivirals; Peptides
- Mechanism of Action Immunostimulants; Neurokinin 1 receptor agonists; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anthrax; Influenza virus infections; Lung disorders; Malignant melanoma; Melioidosis; Pulmonary fibrosis; Radiation injuries; Wounds
- Discontinued Acute asthma; Adult respiratory distress syndrome; Male pattern baldness
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (SC, Injection)